Patient info Open main menu

Seretide 125 Evohaler – Summary of Product Characteristics (SmPC) for healthcare professionals

Text from the MHRA, as of · About this document

Medicine status: Prescription only (POM) Details

The Summary of Product Characteristics (SmPC) is written for healthcare professionals. Patients will find plain advice in the patient information leaflet: how to take, side effects, other medicines, pregnancy and breast-feeding.

Medicine strength:
25 microgram/dose + 125 microgram/dose
Contains active substances:

Summary of Product Characteristics (SmPC) - Seretide 125 Evohaler

1. Trade Name of the Medicinal Product

Not applicable.

2. Qualitative and Quantitative Composition

Not applicable.

3. Pharmaceutical Form

Not applicable.

Clinical Particulars

4.1. Therapeutic Indications

Not applicable.

4.2. Posology and Method of Administration

Not applicable.

4.3. Contra-indications

Not applicable.

4.4. Special Warnings and Precautions for Use

Not applicable.

4.5. Interactions with other Medicaments and other forms of Interaction

Not applicable.

4.6. Pregnancy and Lactation

Not applicable.

4.7. Effects on Ability to Drive and Use Machines

Not applicable.

4.8. Undesirable Effects

Not applicable.

4.9. Overdose

Not applicable.

Pharmacological Properties

5.1. Pharmacodynamic Properties

Not applicable.

5.2. Pharmacokinetic Properties

Not applicable.

5.3. Preclinical Safety Data

Not applicable.

Pharmaceutical Particulars

6.1. List of Excipients

Not applicable.

6.2. Incompatibilities

Not applicable.

6.3. Shelf Life

Not applicable.

6.4. Special Precautions for Storage

Not applicable.

6.5. Nature and Contents of Container

Not applicable.

6.6. Instruction for Use/Handling

Not applicable.

Administrative Data

7. Marketing Authorisation Holder

Not applicable.

8. Marketing Authorisation Number

Not applicable.

9. Date of First Authorisation/Renewal of Authorisation

Not applicable.

10. Date of (Partial) Revision of the Text

Not applicable.

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PLPI 15184/0479

MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Seretide 125 Evohaler

Prescription needed? Yes, prescription-only medicine (POM)
Active substances Salmeterol, Fluticasone
Strength 25 microgram/dose + 125 microgram/dose
Pharmaceutical form Pressurised inhalation
How is it taken Inhalation
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Drug group (ATC)
  1. R Respiratory system drugs
    1. R03 Drugs for obstructive airway diseases
      1. R03A Adrenergics, inhalants
        1. R03AK Adrenergics inhalants in combination with corticosteroids or other drugs, excl. anticholinergics
          1. R03AK06 salmeterol and fluticasone
Marketing authorisation PLPI 15184/0295, PLPI 15184/0479
Codes BNF 03020000

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.1.0 of 12 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.